Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bendamustine
Related studies linked through entity extraction aliases.
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
- Status
- COMPLETED
- Phase
- PHASE1
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Status
- COMPLETED
- Phase
- PHASE2
GIMEMA CLL0809 Study (BendOfa)
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Bendamustine and Bevacizumab for Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE3
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2